Table 1 Sociodemographic and clinical characteristics of the sample
Characteristics | No | Percentage | Mean | SD |
|---|---|---|---|---|
Present age (range 40–81) | 66.1 | 9.9 | ||
≥66 years old | 24 | 61.5 | ||
Gender | ||||
Female | 4 | 10.3 | ||
Male | 35 | 89.7 | ||
Marital status | ||||
Single | 1 | 2.5 | ||
Married | 36 | 92.3 | ||
Widowed | 2 | 5.2 | ||
Limiting comorbidity | 19 | 48.7 | ||
Performance status (range 60–90)a | 79.1 | 8.9 | ||
60–80 | 26 | 66.7 | ||
90 | 13 | 33.3 | ||
Stage | ||||
IV | 35 | 89.7 | ||
III-B | 4 | 10.3 | ||
Histological types | ||||
Adenocarcinoma | 18 | 46.2 | ||
Large-cell carcinoma | 1 | 2.5 | ||
Squamous cell carcinoma | 19 | 48.8 | ||
Adenosquamous carcinoma | 1 | 2.5 | ||
Chemotherapy | ||||
Carboplatin doublet | 29 | 74.4 | ||
Cisplatin doublet | 10 | 25.6 | ||
Morphine | 29 | 74.4 | ||
2nd assessment | ||||
Performance status (range 30–100) | 70.5 | 17.4 | ||
Treatment response | ||||
Progressive disease | 17 | 43.6 | ||
Stable disease | 14 | 35.9 | ||
Partial response | 8 | 20.5 | ||
Toxicity | ||||
Neutropenia | 2 | 5.2 | ||
Thrombopenia | 2 | 5.2 | ||
Vomiting | 1 | 2.6 | ||
Fatigue | 1 | 2.6 | ||
3rd assessment | ||||
Performance status (range 50–90) | 76.8 | 12.1 | ||
Treatment response 3rd assessment | ||||
Progression | 7 | 36.8 | ||
No changes | 12 | 63.2 | ||
Chemotherapy cycles received (range 1–14) median 4 | 5.2 | |||
Platin doublet | 33 | 15.4 | ||
Platin doublet + maintenance treatment | 6 | 84.6 | ||
CT from 3 to 2 weeks | 3 | 7.7 | ||
Time-to-disease progression | ||||
Range 0.93–17.23; median 5.20 | 5.98 | 4.54 | ||
Survival | ||||
Range 2.20–44.63; median 7.45 | 10.99 | 8.92 | ||